Details of Disease

General Information of Disease (ID: DIS6ZHWU)

• Disease Name: Bacillus anthracis infection
• Disease Class: 1G40-1G41: Sepsis
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS6ZHWU: Bacillus anthracis infection
• ICD Code: ICD-11: ICD-11: 1G40

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Biothrax	DMVI7UF	Approved	NA	[1]
Immune globulin	DMX2OMJ	Approved	NA	[2]

This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Solithromycin	DM6QZIA	Phase 3	Small molecular drug	[3]
Alpha-1 antitrypsin	DM5EFXZ	Phase 2	NA	[4]
EA-230	DM6P15C	Phase 2	Peptide	[5]
GC-1109	DMI9FBG	Phase 2	NA	[6]
MIS-416	DM7K4YR	Phase 2	NA	[7]
NasoVAX	DM9Z2MF	Phase 2	NA	[8]
AVP-21D9	DMMWEH6	Phase 1	Antibody	[9]
IQ-DAA	DMHP71R	Phase 1	NA	[10]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anthrax vaccine	DM9GSWY	Discontinued in Phase 1	Vaccine	[11]
Nisin	DM5TNOS	Terminated	NA	[12]

This Disease is Treated as An Indication in 7 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alpha-arylamino hydroxamic acids	DMPA3F9	Investigative	NA	[8]
IB-201	DMQ2C87	Investigative	NA	[8]
MVA-BN anthrax	DM6PNPL	Investigative	NA	[8]
NeuGene	DMP1KEJ	Investigative	NA	[8]
Nfu-PA-D4-RNP	DM887K9	Investigative	NA	[8]
PBI-220	DMDJPBK	Investigative	NA	[8]
VLI-04A	DMMQ7LJ	Investigative	NA	[8]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT00448253) Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT01756339) Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia. U.S. National Institutes of Health.
• [4] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033072)
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041723)
• [6] ClinicalTrials.gov (NCT01624532) A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109. U.S. National Institutes of Health.
• [7] Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis. PLoS ONE 9(1): e87712. January 31, 2014.
• [8] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [9] ClinicalTrials.gov (NCT01202695) Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9). U.S. National Institutes of Health.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020942)
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017549)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005823)